2 hours ago
SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress
SELLAS Life Sciences (SLS) stock soars 255% YTD as Phase 3 AML trial hits critical milestone. Analysts set $10 target amid rising institutional interest.
The post SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress appeared first on Blockonomi.
Source: Blockonomi →Related News
- 50 minutes ago
Regenxbio (RGNX) Stock Plummets 25% as FDA Halts Gene Therapy Trial
- 51 minutes ago
Archer Aviation (ACHR) Stock Soars 19% Following L.A. Live Vertiport Partnership...
- 52 minutes ago
Bernstein Boosts Airbnb (ABNB) Price Target to $217 Following Strong Q2 Performa...
- 53 minutes ago
Taiwan Charges Nvidia (NVDA) and Super Micro Staff in Illegal AI Chip Export Cas...
- 54 minutes ago
American Airlines (AAL) Stock Falls After Q4 Capacity Forecast Reduced Amid Trav...